PL2483278T3 - Związki benzoksazepinowe stanowiące inhibitor pi3k i ich zastosowanie w leczeniu nowotworu - Google Patents
Związki benzoksazepinowe stanowiące inhibitor pi3k i ich zastosowanie w leczeniu nowotworuInfo
- Publication number
- PL2483278T3 PL2483278T3 PL10757213T PL10757213T PL2483278T3 PL 2483278 T3 PL2483278 T3 PL 2483278T3 PL 10757213 T PL10757213 T PL 10757213T PL 10757213 T PL10757213 T PL 10757213T PL 2483278 T3 PL2483278 T3 PL 2483278T3
- Authority
- PL
- Poland
- Prior art keywords
- cancer
- treatment
- inhibitor compounds
- pi3k inhibitor
- benzoxazepin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24638109P | 2009-09-28 | 2009-09-28 | |
US33068510P | 2010-05-03 | 2010-05-03 | |
EP10757213.3A EP2483278B1 (en) | 2009-09-28 | 2010-09-27 | Benzoxazepin pi3k inhibitor compounds and their use in the treatment of cancer |
PCT/EP2010/064208 WO2011036280A1 (en) | 2009-09-28 | 2010-09-27 | Benzoxazepin pi3k inhibitor compounds and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2483278T3 true PL2483278T3 (pl) | 2014-05-30 |
Family
ID=43037239
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL10757213T PL2483278T3 (pl) | 2009-09-28 | 2010-09-27 | Związki benzoksazepinowe stanowiące inhibitor pi3k i ich zastosowanie w leczeniu nowotworu |
Country Status (32)
Country | Link |
---|---|
US (7) | US8242104B2 (pl) |
EP (3) | EP2711368B1 (pl) |
JP (2) | JP5540101B2 (pl) |
KR (1) | KR101428346B1 (pl) |
CN (2) | CN104744491B (pl) |
AR (1) | AR078187A1 (pl) |
AU (1) | AU2010299816C1 (pl) |
BR (1) | BR112012006807A2 (pl) |
CA (1) | CA2772691C (pl) |
CL (1) | CL2012000754A1 (pl) |
CO (1) | CO6491026A2 (pl) |
CR (1) | CR20120121A (pl) |
DK (1) | DK2483278T3 (pl) |
EC (1) | ECSP12011755A (pl) |
ES (2) | ES2570569T3 (pl) |
HK (2) | HK1174629A1 (pl) |
HR (1) | HRP20140229T1 (pl) |
IL (2) | IL217558A (pl) |
MA (1) | MA33531B1 (pl) |
MX (1) | MX2012003591A (pl) |
MY (2) | MY184074A (pl) |
NZ (1) | NZ597833A (pl) |
PE (1) | PE20121025A1 (pl) |
PL (1) | PL2483278T3 (pl) |
PT (1) | PT2483278E (pl) |
RS (1) | RS53164B (pl) |
RU (2) | RU2600927C2 (pl) |
SG (1) | SG10201405049RA (pl) |
SI (1) | SI2483278T1 (pl) |
TW (1) | TWI423980B (pl) |
WO (1) | WO2011036280A1 (pl) |
ZA (1) | ZA201202199B (pl) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2464645T1 (sl) | 2009-07-27 | 2017-10-30 | Gilead Sciences, Inc. | Zlite heterociklične spojine kot ionsko kanalni modulatorji |
UA108863C2 (ru) | 2009-09-28 | 2015-06-25 | Ф. Хоффманн-Ля Рош Аг | Бензоксепиновые ингибиторы pi3 и их применение |
SI2483278T1 (sl) * | 2009-09-28 | 2014-03-31 | F. Hoffmann-La Roche Ag | Inhibitorske spojine benzoksazepina pi3k in njihova uporaba pri zdravljenju raka |
US8703759B2 (en) | 2010-07-02 | 2014-04-22 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
RU2013143747A (ru) | 2011-03-21 | 2015-04-27 | Ф. Хоффманн-Ля Рош Аг | Соединения бензоксазепина, селективные в отношении pi3k p110 дельта и способы их применения |
PT2707361T (pt) | 2011-05-10 | 2017-11-28 | Gilead Sciences Inc | Compostos heterocíclicos fusionados como moduladores do canal de sódio |
WO2012156379A1 (en) | 2011-05-13 | 2012-11-22 | Universität Zürich | PIK3/P110α INHIBITORS FOR PREVENTION OF RESTENOSIS BY APPLICATION AS AN IMPLANT COATING |
TW201837023A (zh) | 2011-07-01 | 2018-10-16 | 美商基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
NO3175985T3 (pl) * | 2011-07-01 | 2018-04-28 | ||
CN104284899A (zh) * | 2012-02-17 | 2015-01-14 | 弗·哈夫曼-拉罗切有限公司 | 三环化合物和其应用方法 |
WO2013182668A1 (en) * | 2012-06-08 | 2013-12-12 | F. Hoffmann-La Roche Ag | Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer |
EP2872161B1 (en) | 2012-06-26 | 2020-12-16 | Del Mar Pharmaceuticals | Dianhydrogalactitol for use in treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations |
CN102775395A (zh) * | 2012-07-12 | 2012-11-14 | 江苏七洲绿色化工股份有限公司 | 一种丙环唑的制备方法及丙环唑中间体 |
IN2015DN00659A (pl) * | 2012-08-07 | 2015-06-26 | Janssen Pharmaceutica Nv | |
KR101871133B1 (ko) | 2013-03-13 | 2018-06-25 | 에프. 호프만-라 로슈 아게 | 벤즈옥사제핀 화합물의 제조 방법 |
EP2983674A4 (en) | 2013-04-08 | 2017-05-10 | Dennis M. Brown | Therapeutic benefit of suboptimally administered chemical compounds |
CN105829323B (zh) | 2013-12-16 | 2019-04-12 | 豪夫迈·罗氏有限公司 | Gdc-0032的多晶型物、其制备方法和药物用途 |
CN106572990A (zh) | 2014-03-13 | 2017-04-19 | 豪夫迈·罗氏有限公司 | 含有雌激素受体调节剂的治疗性组合产品 |
IL280856B (en) | 2015-02-02 | 2022-09-01 | Forma Therapeutics Inc | 3-Alkyl-4-amino-[0,5,4] bicyclic hydroxamic acids as hdac inhibitors |
TW201636329A (zh) | 2015-02-02 | 2016-10-16 | 佛瑪治療公司 | 作為hdac抑制劑之雙環[4,6,0]異羥肟酸 |
AR104068A1 (es) | 2015-03-26 | 2017-06-21 | Hoffmann La Roche | Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer |
EP3288948B1 (en) * | 2015-04-30 | 2019-11-20 | Novartis AG | Fused tricyclic pyrazole derivatives useful for modulating farnesoid x receptors |
US20160375033A1 (en) | 2015-06-29 | 2016-12-29 | Genentech, Inc. | Methods of treatment with taselisib |
RS59740B1 (sr) * | 2015-07-02 | 2020-02-28 | Hoffmann La Roche | Benzoksazepin oksazolidinonska jedinjenja i postupci upotrebe |
EP3317283B1 (en) | 2015-07-02 | 2019-04-03 | H. Hoffnabb-La Roche Ag | Benzoxazepin oxazolidinone compounds and methods of use |
CN112409378A (zh) | 2015-09-08 | 2021-02-26 | 豪夫迈·罗氏有限公司 | 三环pi3k抑制剂化合物及其使用方法 |
US9721369B2 (en) * | 2015-09-15 | 2017-08-01 | Facebook, Inc. | Systems and methods for utilizing multiple map portions from multiple map data sources |
EP3472131B1 (en) | 2016-06-17 | 2020-02-19 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors |
TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
JP2019530688A (ja) | 2016-09-29 | 2019-10-24 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 新規5−置換イミダゾリルメチル誘導体 |
PL3555107T3 (pl) | 2016-12-15 | 2021-07-05 | F. Hoffmann-La Roche Ag | Sposób wytwarzania (S)-2-((2-((S)-4-(difluorometylo)-2-oksooksazolidyn-3-ylo)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oksazepin-9-ylo)amino)propanamidu |
CN117180422A (zh) | 2017-03-02 | 2023-12-08 | 豪夫迈·罗氏有限公司 | Her2阳性乳腺癌的辅助治疗 |
CN110650963B (zh) * | 2017-04-28 | 2022-09-27 | 豪夫迈·罗氏有限公司 | Gdc-0077的多晶型物和固体形式及其制备方法 |
IL274027B2 (en) * | 2017-10-26 | 2023-12-01 | Xynomic Pharmaceuticals Inc | B–RAF kinase inhibitor salt crystals |
JP7456945B2 (ja) * | 2018-05-30 | 2024-03-27 | 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 | 三環式誘導体を含む阻害剤、その製造方法、及び使用 |
CN111909157B (zh) * | 2019-05-07 | 2023-02-03 | 南京药石科技股份有限公司 | Ezh2抑制剂及其用途 |
BR112022008647A2 (pt) * | 2019-11-04 | 2022-07-19 | Betta Pharmaceuticals Co Ltd | Composto de imidazolidinona, método de preparação do mesmo e uso do mesmo |
WO2021088845A1 (zh) * | 2019-11-04 | 2021-05-14 | 贝达药业股份有限公司 | 咪唑烷酮类化合物及其制备方法与应用 |
EP4067363A4 (en) * | 2019-11-25 | 2023-12-27 | Shanghai Hansoh Biomedical Co., Ltd. | SALT OR CRYSTAL FORM HAVING THREE CONDENSED RINGS AND PHARMACEUTICAL COMPOSITION THEREOF |
EP4353729A1 (en) * | 2021-05-13 | 2024-04-17 | Betta Pharmaceuticals Co., Ltd | Polymorph of imidazolidinone compound, preparation method therefor and use thereof |
CA3220273A1 (en) | 2021-05-28 | 2022-12-01 | Genentech, Inc. | Process for the preparation of benzoxazepin oxazolidinone compounds |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
GB8504702D0 (en) | 1985-02-23 | 1985-03-27 | Zyma Sa | Tricyclic compounds |
US5583024A (en) | 1985-12-02 | 1996-12-10 | The Regents Of The University Of California | Recombinant expression of Coleoptera luciferase |
FR2677356B1 (fr) | 1991-06-05 | 1995-03-17 | Sanofi Sa | Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant. |
DK0638071T3 (da) | 1992-12-28 | 1997-10-27 | Eisai Co Ltd | Heterocykliske carboxylsyrederivater, der bindes til retenoidreceptorer (RAR) |
AU678503B2 (en) * | 1993-09-24 | 1997-05-29 | Takeda Chemical Industries Ltd. | Condensed heterocyclic compounds and their use as squalene synthetase inhibitors |
US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
JPH08336393A (ja) | 1995-04-13 | 1996-12-24 | Mitsubishi Chem Corp | 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法 |
EP0876375A1 (en) | 1995-11-17 | 1998-11-11 | E.I. Du Pont De Nemours And Company | Tricyclic herbicidal heterocycles |
US6602677B1 (en) | 1997-09-19 | 2003-08-05 | Promega Corporation | Thermostable luciferases and methods of production |
DE19908535A1 (de) | 1999-02-26 | 2000-08-31 | Aventis Pharma Gmbh | Verwendung von polycyclischen Thiazol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas |
DE19908533A1 (de) | 1999-02-26 | 2000-08-31 | Aventis Pharma Gmbh | Polycyclische Thiazol-Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen |
DE19908538A1 (de) | 1999-02-26 | 2000-08-31 | Aventis Pharma Gmbh | Polycyclische 2-Amino-Thiazol Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen |
DE19908537A1 (de) | 1999-02-26 | 2000-08-31 | Aventis Pharma Gmbh | Verwendung von polycyclischen 2-Amino-Thiazol Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas |
US7273880B2 (en) | 1999-06-30 | 2007-09-25 | H. Lunbeck A/S | Selective NPY (Y5) antagonists |
WO2001064675A1 (en) | 2000-03-03 | 2001-09-07 | Novartis Ag | Condensed thiazolamines and their use as neuropeptide y5 antagonists |
SK9782003A3 (en) | 2001-02-02 | 2004-01-08 | Schering Corp | 3,4-Di-substituted cyclobutene-1,2-diones as CXC chemokine receptor antagonists |
TWI232863B (en) * | 2001-06-11 | 2005-05-21 | Akzo Nobel Nv | Benzoxazepine derivatives |
BR0312780A (pt) | 2002-07-19 | 2005-05-03 | Pharmacia Corp | Compostos de tiofeno-carboxamida substituìda para o tratamento de inflamação |
WO2004069245A1 (en) * | 2003-02-07 | 2004-08-19 | Warner-Lambert Company Llc | Oxazolidinone derivates n-substituted by a tricyclic ring, for use as antibacterial agents |
TW200510356A (en) * | 2003-08-01 | 2005-03-16 | Takeda Chemical Industries Ltd | Benzoxaepine compounds |
US20050239767A1 (en) | 2003-10-28 | 2005-10-27 | Chan Michael K | Intermolecular SNAr of the heterocycle-activated nitro and fluoro groups-application in the synthesis of polyazamacrocyclic ligands |
BRPI0512832A (pt) * | 2004-07-01 | 2008-04-08 | Merck & Co Inc | composto ou um sal ou estereoisÈmero farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para usar um composto |
AU2005293607A1 (en) | 2004-10-07 | 2006-04-20 | Boehringer Ingelheim International Gmbh | PI3 kinases |
AU2006302415B2 (en) | 2005-10-07 | 2012-09-13 | Exelixis, Inc. | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
US20070238718A1 (en) * | 2006-04-06 | 2007-10-11 | Matthias Grauert | Thiazolyl-dihydro-indazole |
US20070238746A1 (en) * | 2006-04-06 | 2007-10-11 | Trixi Brandl | Thiazolyl-dihydro-chinazoline |
GB0610866D0 (en) * | 2006-06-02 | 2006-07-12 | Hammersmith Imanet Ltd | Novel in vivo imaging compounds |
US20080026171A1 (en) * | 2006-07-28 | 2008-01-31 | Alcan Packaging Flexible France | Coextruded film with polylactic acid (PLA) and Ethylene Vinyl Acetate (EVA) |
EP2054058B1 (en) | 2006-08-04 | 2016-11-09 | Beth Israel Deaconess Medical Center | Inhibitors of pyruvate kinase and methods of treating disease |
US8779154B2 (en) | 2006-09-26 | 2014-07-15 | Qinglin Che | Fused ring compounds for inflammation and immune-related uses |
RU2485114C2 (ru) * | 2006-12-29 | 2013-06-20 | Эбботт Гмбх Унд Ко.Кг | Карбоксамидные соединения и их применение в качестве ингибиторов кальпаинов |
KR101546080B1 (ko) | 2007-09-19 | 2015-08-20 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | 면역 활성화 및 선택된 암의 영상화를 위한 양성자방출 단층촬영 프로브 |
CL2009000780A1 (es) | 2008-03-31 | 2010-01-15 | Genentech Inc | Compuestos derivados de heterociclil-pirano-heterociclilo, heterociclil-oxepina-heterociclilo, benzopirano-heterociclilo y benzoxepina-heterociclilo sustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion; kit farmaceutico; y su uso en el tratamiento del cancer, mediado por la inhibicion de pi3k. |
EP2350084B1 (en) * | 2008-10-17 | 2015-06-24 | Boehringer Ingelheim International GmbH | Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (pi3-kinases) inhibitor |
UA108863C2 (ru) * | 2009-09-28 | 2015-06-25 | Ф. Хоффманн-Ля Рош Аг | Бензоксепиновые ингибиторы pi3 и их применение |
SI2483278T1 (sl) * | 2009-09-28 | 2014-03-31 | F. Hoffmann-La Roche Ag | Inhibitorske spojine benzoksazepina pi3k in njihova uporaba pri zdravljenju raka |
-
2010
- 2010-09-27 SI SI201030536T patent/SI2483278T1/sl unknown
- 2010-09-27 DK DK10757213.3T patent/DK2483278T3/da active
- 2010-09-27 SG SG10201405049RA patent/SG10201405049RA/en unknown
- 2010-09-27 WO PCT/EP2010/064208 patent/WO2011036280A1/en active Application Filing
- 2010-09-27 CN CN201510043641.XA patent/CN104744491B/zh active Active
- 2010-09-27 BR BR112012006807-5A patent/BR112012006807A2/pt not_active Application Discontinuation
- 2010-09-27 ES ES13193562T patent/ES2570569T3/es active Active
- 2010-09-27 AR ARP100103491A patent/AR078187A1/es unknown
- 2010-09-27 CN CN201080053938.XA patent/CN102762576B/zh active Active
- 2010-09-27 MY MYPI2015002473A patent/MY184074A/en unknown
- 2010-09-27 EP EP13193562.9A patent/EP2711368B1/en active Active
- 2010-09-27 KR KR1020127010974A patent/KR101428346B1/ko active IP Right Review Request
- 2010-09-27 RU RU2012117398/04A patent/RU2600927C2/ru active
- 2010-09-27 NZ NZ597833A patent/NZ597833A/en unknown
- 2010-09-27 MX MX2012003591A patent/MX2012003591A/es active IP Right Grant
- 2010-09-27 MY MYPI2012000823A patent/MY160064A/en unknown
- 2010-09-27 RS RS20140060A patent/RS53164B/en unknown
- 2010-09-27 RU RU2016105810A patent/RU2654068C1/ru active
- 2010-09-27 ES ES10757213.3T patent/ES2444779T3/es active Active
- 2010-09-27 TW TW099132661A patent/TWI423980B/zh active
- 2010-09-27 EP EP10757213.3A patent/EP2483278B1/en active Active
- 2010-09-27 CA CA2772691A patent/CA2772691C/en active Active
- 2010-09-27 US US12/890,812 patent/US8242104B2/en active Active
- 2010-09-27 EP EP20140190276 patent/EP2845592A1/en not_active Withdrawn
- 2010-09-27 PE PE2012000390A patent/PE20121025A1/es active IP Right Grant
- 2010-09-27 JP JP2012530282A patent/JP5540101B2/ja active Active
- 2010-09-27 PT PT107572133T patent/PT2483278E/pt unknown
- 2010-09-27 AU AU2010299816A patent/AU2010299816C1/en active Active
- 2010-09-27 PL PL10757213T patent/PL2483278T3/pl unknown
-
2012
- 2012-01-10 CO CO12002995A patent/CO6491026A2/es active IP Right Grant
- 2012-01-16 IL IL217558A patent/IL217558A/en active IP Right Grant
- 2012-02-15 MA MA34637A patent/MA33531B1/fr unknown
- 2012-03-13 CR CR20120121A patent/CR20120121A/es unknown
- 2012-03-26 ZA ZA2012/02199A patent/ZA201202199B/en unknown
- 2012-03-27 CL CL2012000754A patent/CL2012000754A1/es unknown
- 2012-03-28 EC ECSP12011755 patent/ECSP12011755A/es unknown
- 2012-05-22 US US13/477,587 patent/US8343955B2/en active Active
- 2012-11-20 US US13/681,763 patent/US8586574B2/en active Active
-
2013
- 2013-02-07 HK HK13101739.9A patent/HK1174629A1/xx unknown
- 2013-02-07 HK HK15112815.1A patent/HK1211929A1/xx unknown
- 2013-10-07 US US14/047,206 patent/US8785626B2/en active Active
- 2013-11-01 JP JP2013228826A patent/JP5625101B2/ja active Active
-
2014
- 2014-03-12 HR HRP20140229AT patent/HRP20140229T1/hr unknown
- 2014-06-05 US US14/297,142 patent/US9198918B2/en active Active
-
2015
- 2015-05-28 IL IL239081A patent/IL239081B/en active IP Right Grant
- 2015-11-03 US US14/930,929 patent/US9546178B2/en active Active
-
2016
- 2016-12-05 US US15/368,937 patent/US9670228B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2483278T3 (pl) | Związki benzoksazepinowe stanowiące inhibitor pi3k i ich zastosowanie w leczeniu nowotworu | |
IL219253A (en) | Benzodiazepine inhibiting bromodomain for cancer treatment | |
ZA201207574B (en) | Phytocannabinoids in the treatment of cancer | |
ZA201202384B (en) | Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer | |
ZA201201434B (en) | Use of metformin in cancer treatment and prevention | |
PL2556071T3 (pl) | Inhibitory kinaz i ich zastosowanie w leczeniu raka | |
PL2101731T3 (pl) | Endoksyfen do zastosowania w leczeniu nowotworu | |
IL214349A (en) | Preparations for the treatment of cancer and the use of cellulose energy inhibitors to create them | |
HK1256479A1 (zh) | 在治療癌症中grn163l用作端粒酶抑制劑 | |
EP2651894A4 (en) | THIOSEMICARBAZONE COMPOUNDS FOR CANCER TREATMENT | |
IL202307A0 (en) | Multikinase inhibitors for use in the treatment of cancer | |
EP2437738A4 (en) | METHOD AND COMPOSITIONS FOR CANCER TREATMENT | |
HK1151971A1 (en) | Compounds for use in the treatment of cancer | |
EP2744786A4 (en) | SUBSTITUTED 2-IMIDAZOLIDINONE AND 2-IMIDAZOLONE AND THEIR USE IN THE TREATMENT OF CANCER | |
EP2411031A4 (en) | Methods and compositions for the treatment of cancer | |
GB201718726D0 (en) | Phytocannabinoids in the treatment of cancer | |
HUP1000688A2 (en) | Use of trifluoro-phthalimides in the treatment of cancer | |
RS55471B1 (sr) | Inhibitori kinaze i njihova upotreba za lečenje kancera |